Pharmaceuticals, Biotechnology & Life Sciences

AbbVie’s bold moves—FDA‑approved blood cancer combo, oncology breakthroughs, and growing women’s health focus—show how the $397B biotech leader keeps leading the pharma frontier while delivering dividends and investor value.

Protalix BioTherapeutics: plant‑cell tech, €CHMP approval for Elfabrio and solid NYSE American performance, showing growth in rare‑disease biotech.

Explore CSL Limited’s biotech strengths, market value and recent partnership with Eli Lilly—insights for investors on a leading Australian health‑care firm.

Serina Therapeutics (SER) focuses on regenerative, anti‑aging biotech; analyze its current market, clinical pipeline, and potential upside for investors.

Abivax’s obefazimod shows early anti‑fibrotic and symptomatic benefits in Crohn’s, with strong safety and regulatory progress highlighted at ECCO 2026.

Medexus Pharmaceuticals reports strong Q3 2026 earnings, with GRAFAPEX driving growth across rheumatology, oncology and pediatrics, despite a negative PE ratio.

Ocular Therapeutix faces analyst optimism and mixed clinical results as its hydrogel eye therapy shows modest gains; investors weigh high target prices against realistic performance.

Explore how Sarepta’s Elevidys patent battle could shape its stock, revenue, and future gene‑therapy growth.

Exact Sciences Corp’s stock near 52‑week high shows strong investor confidence as its groundbreaking stool‑based colorectal cancer screening tech gains traction.

Explore MannKind’s biotech journey—high P/E optimism, volatile stock, and conference insights on its innovative diabetes, cancer, and autoimmune therapies.